A simple and sensitive validated HPLC method for quantitative determination of cisplatin in human plasma

Clinical Research and Regulatory Affairs

Volumn 27, Issue 1, 2010, Pages 1-6

  Kaushik, K Harish ^a   Sripuram, Vijay K ^a   Bedada, Satish ^a   Reddy, Narsimha Y ^a   Priyadarshini, G Indira ^b   Devarakonda, Krishna R ^c  

^a KAKATIYA UNIVERSITY   (India)

^b ANDHRA UNIVERSITY   (India)

^c MEDTRONIC INC   (United States)

Author keywords

Cisplatin; Ethanol; HPLC; Human plasma

Indexed keywords

ACETONITRILE; CHLOROFORM; CISPLATIN; METHANOL; PLATIFIRST; UNCLASSIFIED DRUG;

ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; DRUG SELECTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID LIQUID EXTRACTION; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 77749316962     PISSN: 10601333     EISSN: 15322521     Source Type: Journal    
DOI: 10.3109/10601330903490462     Document Type: Article

References (16)

1. Walker EM Jr, Walker SM. Evolution of chemotherapy with platinum compounds. Ann Clin Lab Sci 1999;29:263-274.
2. Dobyan DC, Levi J, Jacobs C, Kosek J, Weiner MW. Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther 1980;213:551-556.
3. Thomson SW, Davis LE, Kornfeld M, Hilgers RD, Standefer JC. Cisplatin neuropathy: clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 1984;54:1269-1275.
4. Williams PD. The application of renal cells in culture in studying drug-induced nephrotoxicity. In Vitro Cell Dev Biol 1989;25:800-805.
5. Safirstein R, Miller P, Guttenplan JB. Uptake and metabolism of cisplatin by rat kidney. Kidney Int 1984;25:753-758.
6. Jones BR, Bhalla RB, Mladek J, Kaleya RN, Gralla RJ, Alcock NW, Schwartz MK, Young CW, Reidenberg MM. Comparison of methods of evaluating nephrotoxicity of cis- platinum. Clin Pharmacol Ther 1980;27:557-562.
7. El-Yazigi1 A, Amer M, Martin CR. Pharmacokinetics of platinum in cancer patients treated with carboplatin in combination with high-dose methotrexate. Cancer Res 1984;44:1693.
8. Newell DR, Siddik ZH, Harrap KR. In:Reid,Wilson, editors. Drug determination in therapeutic and forensic contexts. New York: Plenum Press; 1985. p 145.
9. Ma J, Stoter G, Verweij J, Schellens JHM. Comparison of ethanol plasma-protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations. Cancer Chemother Pharmacol 1996;38:391-394.
10. Reece PA, Bishop JF, Olver IN, Stafford I, Hillcoat BL, Morstyn G. A preliminary pharmacokinetic study of docetaxel, carboplatin and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 1987;19:326.
11. Tyczkowska K, Page RL, Riviere JE. Simple and rapid determination of carboplatin in plasma by high-performance liquid chromatography. Error pattern and application to clinical pharmacokinetic studies. Journal of chromatography B 2001;764:457-464.
12. Kizu R, Yamamoto T, Yokoyama T, Tanaka M, Miyazaki M. A sensitive post coloumn derivatisation/UV detection system for HPLC determination of antitumour divalent and quadrivalent platinum complexes. Chem Pharm Bull 1995;43:108.
13. Marsh KC, Sternson LA, Repta AJ. Post coloumn reaction detector for platinum(II) Antineoplastic agents. Anal Chem 1984;56:491.
14. Gooijer C, Veltkamp AC, Baumann RA, Velthors NH, Frei RW, van der Vijgh WJF. Analysis of platinum complexes by liquid chromatography with quenched phosphoresence detection. J Chromatogr 1984;312:337.
15. Kaushik HK, Kumar VS, Kumar SB, Reddy N, Raghavaiah VK, Devarakonda KR. Population pharmacokinetics of cisplatin in Asian Indian cancer patients. Clin Res Regulat Affairs 2009;26:84-92.
16. Guidance for industry, bioanalytical method validation. U.S. Department of Health and Human Services, Food and Drug Administration(FDA),Center for Drug Evaluation and Research (CDER); Rockville, USA. 2001.